• SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

  NCT04650490

  WithdrawnInterventionalPhase 2Updated Mar 2, 2023
• Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

  NCT01644591

  Active, not recruitingInterventionalPhase 2Updated Aug 20, 2026
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

  NCT05341349

  TerminatedInterventionalPhase 1Updated Apr 23, 2026
• Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

  NCT04516070

  Active, not recruitingInterventionalPhase 2Updated Mar 5, 2026
• A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

  NCT05419076

  RecruitingInterventionalPhase 2Updated Jun 10, 2026
• A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

  NCT03497767

  CompletedInterventionalPhase 2Updated May 31, 2024

ClinicalTrials.gov ID

NCT05522660

Lead Sponsor

ETOP IBCSG Partners FoundationNETWORK

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

180Estimated

Last Update Posted

Apr 27, 2026Actual

Start Date

Nov 30, 2022Actual

Primary Completion Date

Sep 2026Estimated

Completion Date

Dec 2026Estimated

Official Title

A Multicentre Randomised Open-label Phase III Study of Stereotactic Radiosurgery, in Addition to Standard Systemic Therapy for Patients With Metastatic Melanoma or Newly Diagnosed Metastatic NSCLC and Asymptomatic or Oligo-symptomatic Brain Metastases

Brief Summary

The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.

• Non-Small Cell Lung Cancer
• Melanoma

• Stereotactic radiosurgery
• Immune checkpoint inhibitor

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Most important inclusion criteria:

• Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.

• Requirements for brain metastases:

• Brain metastases must be previously untreated, except for surgery.

• Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.

• Number and size of metastases at diagnosis of brain metastases:

  • Maximum 1-10 brain metastases at screening
  • At least one brain metastasis must be of ≥5 mm in diameter
  • In case of 1-4 brain metastases:
  • Longest diameter of largest brain metastasis must be ≤30 mm
  • In case of 5-10 brain metastases:
  • Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
  • Maximum cumulative brain metastases volume must be ≤30 mL

• Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC

• Requirements for patients with melanoma:

• Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).

• BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).

• Requirements for patients with NSCLC:

• Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.

• Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)

• Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).

• Age of 18 years or older

• Karnofsky performance status of 60 or more

• Life expectancy >12 weeks

• Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).

• Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.

• Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.

Most important exclusion criteria:

• Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
• Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
• Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
• Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
• Prior whole brain irradiation or focal radiation therapy to the brain
• Prior systemic treatment for brain metastases
• Contra-indication for SRS
• Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
• Women who are pregnant or in the period of lactation.
• Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

ETOP IBCSG Partners FoundationNETWORK

Collaborators

USZ FoundationUNKNOWN

p.baas@nki.nl

ekin.ermis@insel.ch